SUPPLEMENTARY MATERIAL

Received 21 January 2007/Returned for modification 1 March 2007/Accepted 22 March 2007

CLINICAL AND VACCINE IMMUNOLOGY, June 2007, p. 775 781 Vol. 14, No. 6 1556-6811/07/$08.00 0 doi:10.1128/cvi.00043-07 Copyright 2007, American Society for Microbiology. All Rights Reserved. Evaluation of

Loss of CD96 Expression as a New Biomarker for T-cell Senescence in HIV-1 Infection

Loss of CD96 Expression as a New Biomarker for T-cell Senescence in HIV-1 Infection Mohamed El-Far, PhD CHUM research center (CRCHUM) University of Montreal, QC Canada 6th International Workshop on HIV

CoMPAREd to GERMAny: the CAsE of MAlARIA?

december 2, 2011 Eu Ro PE An JouR nal of MEd I CAl RE search 519 Eur J Med Res (2011) 16: 519-525 I. Holzapfel Publishers 2011 ConstItutIvE ACtIvAtIon And ACCElERAtEd MAtuRAtIon of PERIPHERAl Blood t CElls

IAS 2013 Towards an HIV Cure Symposium

In chronically HIV-1-infected patients long-term antiretroviral therapy initiated above 500 CD4/mm 3 achieves better HIV-1 reservoirs' depletion and T-cell count restoration IAS 2013 Towards an HIV Cure

IgG3 regulates tissue-like memory B cells in HIV-infected individuals

SUPPLEMENTARY INFORMATION Articles https://doi.org/10.1038/s41590-018-0180-5 In the format provided by the authors and unedited. IgG3 regulates tissue-like memory B cells in HIV-infected individuals Lela

Pediatric HIV: Immunologic and Virologic Response to Antiretroviral Therapy. Kristjana Hrönn Ásbjörnsdóttir. A dissertation

Pediatric HIV: Immunologic and Virologic Response to Antiretroviral Therapy Kristjana Hrönn Ásbjörnsdóttir A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of

HIV-HBV coinfection in HIV population horizontally infected in early childhood between

UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA FACULTY OF MEDICINE HIV-HBV coinfection in HIV population horizontally infected in early childhood between 1987-1990 Supervising professor: Prof. Cupşa Augustin

Dr Melanie Rosenvinge

18 th Annual Conference of the British HIV Association (BHIVA) Dr Melanie Rosenvinge St George s Hospital NHS Trust, London 1820 April 2012, The International Convention Centre, Birmingham A multicentre

HD1 (FLU) HD2 (EBV) HD2 (FLU)

ramer staining + anti-pe beads ramer staining a HD1 (FLU) HD2 (EBV) HD2 (FLU).73.11.56.46.24 1.12 b CD127 + c CD127 + d CD127 - e CD127 - PD1 - PD1 + PD1 + PD1-1 1 1 1 %CD127 + PD1-8 6 4 2 + anti-pe %CD127

High rates of financial crisis, food insecurity and detectable viral loads in those referred for nutrition support

High rates of financial crisis, food insecurity and detectable viral loads in those referred for nutrition support S.E. Pelham Burn 1, S. Robinson 1, H.S. Jones 1, A. Duncan 2 1 The Food Chain, London,

CHERUB Collaborative HIV Eradication of Reservoirs: UK BRC (

CHERUB Collaborative HIV Eradication of Reservoirs: UK BRC (www.cherub.uk.net) The effect of time to viral suppression at primary HIV infection on long term immunological recovery BHIVA Spring Conference

References: 1. XVI International AIDS Conference, 2006 Abstract no. ThPE0120 2. Bergshoeff A, Burger D, Farrelly L e t al. Pharmacokinetics of once daily vs. twice daily lamivudine and abacavir in HIV-Infected

Supplementary Figure 1. Gating strategy and quantification of integrated HIV DNA in sorted CD4 + T-cell subsets.

Supplementary information HIV reservoir size and persistence are driven by T-cell survival and homeostatic proliferation. Chomont, N., M. El Far, P. Ancuta, L. Trautmann, F. A. Procopio, B. Yassine-Diab,

1. Africa Centre for Health and Population Studies 2. London School of Hygiene and Tropical Medicine 3. University College London

A systematic review of the effects of interrupted antiretroviral interventions for prevention of mother-to-child transmission of HIV on maternal disease progression and survival Naidu KK 1, Mori R 2, Newell

The CAPRI-T was one of two (along with the CAPRI-NK, see reference. [29]) basic immunological studies nested within the CAMELIA trial.

1 SUPPLEMENTARY INFORMATION Patient description and recruitment The CAPRI-T was one of two (along with the CAPRI-NK, see reference [29]) basic immunological studies nested within the CAMELIA trial. Patients

Supplementary Figure 1

Supplementary Figure 1 Supplementary Figure 1: Cryopreservation alters CD62L expression by CD4 T cells. Freshly isolated (left) or cryopreserved PBMCs (right) were stained with the mix of antibodies described

HIV treatment interruptions are associated with heightened biomarkers of inflammation, coagulopathy and T-cell activation despite viral suppression

HIV treatment interruptions are associated with heightened biomarkers of inflammation, coagulopathy and T-cell activation despite viral suppression Nicholas Musinguzi on behalf of Jose Castillo-Mancila,

Supplementary Material*

Supplementary Material* Park LS, Tate JP, Sigel K, Brown ST, Crothers K, Gibert C, et al. Association of Viral Suppression With Lower AIDS-Defining and Non AIDS-Defining Cancer Incidence in HIV-Infected

HIV viral load decay after initiation of HAART: is time to undetectability a valuable clinical parameter?

HIV viral load decay after initiation of HAART: is time to undetectability a valuable clinical parameter? E.Motté, S.Allard, R.Mertens, A.Van Raemdonck, A.De Bel, D.Coomans, P.Lacor Department of Internal

Impact of HIV-1 Drug Resistance Testing on Clinical Outcome of Patients Receiving Highly Active Antiretroviral Therapy in Barbados

Impact of HIV-1 Drug Resistance Testing on Clinical Outcome of Patients Receiving Highly Active Antiretroviral Therapy in Barbados Songee Beckles, Ministry of Health NHAC Symposium December 3 rd 2012,

HIV-1 Subtypes: An Overview. Anna Maria Geretti Royal Free Hospital

HIV-1 Subtypes: An Overview Anna Maria Geretti Royal Free Hospital Group M Subtypes A (1, 2, 3) B C D F (1, 2) G H J K Mechanisms of HIV-1 genetic diversification Point mutations RT error rate: ~1 per

SECONDARY OBJECTIVES:

Study No.: 112 419 Title: Retrospective study using the NADIS database of the reasons for discontinuing the Abacavir-Lamivudine combination in HIV-infected patients treated by an antiretroviral regimen

Immunological biomarkers predictive of clinical response to chemotherapy and maintenance HAART in HIV + patients with Kaposi sarcoma

P909 Immunological biomarkers predictive of clinical response to chemotherapy and maintenance HAART in HIV + patients with Kaposi sarcoma Tedeschi R, Bidoli E 2, Bortolin MT, Pratesi C, Basaglia G, Zanussi

Treatment experience in South Africa. Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand

Treatment experience in South Africa Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand Overview South African Prevalence Adherence Combination ddi + d4t Nevirapine Hepatotoxicity

Socio-Demographic Factors associated with Success of Antiretroviral Treatment among HIV Patients in Tanzania

Socio-Demographic Factors associated with Success of Antiretroviral Treatment among HIV Patients in Tanzania Dr. Fausta Franklin Mosha (MD, MSc, MSc, PHD) Ministry of Health and Social Welfare 22 nd October

Antiviral Therapy 14:

Antiviral Therapy 14:451 457 Short communication CD4 + T-cell percentage is an independent predictor of clinical progression in AIDS-free antiretroviral-naive patients with CD4 + T-cell counts >200 cells/mm

Safety of switching raltegravir 400mg twice daily to raltegravir 800mg once daily in virologically suppressed patients

Safety of switching raltegravir 400mg twice daily to raltegravir 800mg once daily in virologically suppressed patients Amy Moore, Sonali Sonecha, Tristan Barber, Anton Pozniak, David Asboe, Marta Boffito

Effect of Highly Active Antiretroviral Therapy on T-Cell Sub-population Profile in Human Immunodeficiency Virus-1 Infected Patients

International Journal of Immunology 2015; 3(6): 57-71 Published online November 25, 2015 (http://www.sciencepublishinggroup.com/j/iji) doi: 10.11648/j.iji.20150306.11 ISSN: 2329-177X (Print); ISSN: 2329-1753

Resistance Workshop. 3rd European HIV Drug

3rd European HIV Drug Resistance Workshop March 30-April 1 st, 2005 Christine Hughes, PharmD Clinical Associate Professor Faculty of Pharmacy & Pharmaceutical Sciences University of Alberta Tenofovir resistance

Integrase strand-transfer inhibitors primary resistance in patients with acute/recent HIV infection

Integrase strand-transfer inhibitors primary resistance in patients with acute/recent HIV infection Juan Ambrosioni, David Nicolás, Christian Manzardo, Fernando Agüero, José Luis Blanco, Maria del Mar

PERCENTAGE OF CD8/38 T CELLS PRE AND POST ANTI RETROVIRAL THERAPY AMONG HIV INFECTED PATIENTS

PERCENTAGE OF CD8/38 T CELLS PRE AND POST ANTI RETROVIRAL THERAPY AMONG HIV INFECTED PATIENTS PUBLICATION ARTICLE To meet requirements To achieve the Degree of Clinical Pathology Specialist Prepared by:

Coagulation and Morbidity in Treated HIV Infection. Michael M. Lederman, MD Scott R. Inkley Professor of Medicine Case Western Reserve University

Coagulation and Morbidity in Treated HIV Infection Michael M. Lederman, MD Scott R. Inkley Professor of Medicine Case Western Reserve University Although survival has improved, predicted life expectancy

The effect of lamivudine- versus tenofovir-containing antiretroviral regimen on hepatitis B infection in a cohort of HIV infected long term survivors

The effect of lamivudine- versus tenofovir-containing antiretroviral regimen on hepatitis B infection in a cohort of HIV infected long term survivors Aura Temereanca 1,2, Luminita Ene 3, Adelina Rosca

Initiation of antiretrovirals in HIV/HCV co-infected MSM: Are we too late?

Initiation of antiretrovirals in HIV/HCV co-infected MSM: Are we too late? Thomas Martin, Sophie Jose, Alicia Thornton, Natasha Martin, Caroline Sabin, Mark Nelson Background Antiretroviral therapy (ART)

Summarizing current approach to HIV treatment

The Implication of Viral Load Measurement in Assessing the Epidemiologic Control of HIV/AIDS SS Lee, Professor of Infectious Diseases May 2015 Summarizing current approach to HIV treatment Combination

Evolving Realities of HIV Treatment in Resource-limited Settings

Evolving Realities of HIV Treatment in Resource-limited Settings Papa Salif Sow MD, MSc Department of Infectious Diseases University of Dakar, Senegal Introduction: ARV access in RLS Scale-up of ART has

ankylosing spondylitis Department of Clinical Immunology, Xijing Hospital, The Fourth Military

Functional defects in CD4 + CD25 high FoxP3 + regulatory cells in ankylosing spondylitis Huifang Guo 1, 2, 3, Ming Zheng 1, 2, 3, Kui Zhang 1, 3, Fengfan Yang 1, 3, Xin Zhang 1, 3, Qing Han 1, 3, Zhi-Nan

Alexander O. Pasternak, Mirte Scherpenisse, Ben Berkhout

Cell-associated HIV-1 unspliced to multiply spliced RNA ratio at 12 weeks ART correlates with markers of immune activation and apoptosis and predicts the CD4 + T-cell count at 96 weeks ART Alexander O.

T Memory Stem Cells: A Long-term Reservoir for HIV-1

Towards an HIV Cure Pre-Conference Symposium 20 & 21 July 2012 T Memory Stem Cells: A Long-term Reservoir for HIV-1 Maria J Buzon, PhD Ragon Institute of MGH, MIT and Harvard, Massachussetts General Hospital,

Supervised Treatment Interruption (STI) in an Urban HIV Clinical Practice: A Prospective Analysis.

Supervised Treatment Interruption (STI) in an Urban HIV Clinical Practice: A Prospective Analysis. J.L. YOZVIAK 1, P. KOUVATSOS 2, R.E. DOERFLER 3, W.C. WOODWARD 3 1 Philadelphia College of Osteopathic

EVIDENCE FOR LOWER CD4 + T CELL AND HIGHER VIRAL LOAD IN ASYMPTOMATIC HIV-1 INFECTED INDIVIDUALS OF INDIA: IMPLICATIONS FOR THERAPY INITIATION

Indian Journal of Medical Microbiology, (2008) 26(3): 217-21 Special Article EVIDENCE FOR LOWER CD4 + T CELL AND HIGHER VIRAL LOAD IN ASYMPTOMATIC HIV-1 INFECTED INDIVIDUALS OF INDIA: IMPLICATIONS FOR

The EuResist GEIE data base

Prediction Of Antiretroviral Therapy Outcomes In Poor Resource Countries: Comparison Between Genotype Resistance Testing Based vs. Treatment History Models MCFProsperi 1,MRosen Zvi 2,AAltmann 3,EAharoni

C. Shou 1, n. Weng 1, y. Jin 1, l. feng 2, C. Jin 1, S. Hoextermann 3, a. Potthoff 3, a. Skaletz-Rorowski 3, n. H. brockmeyer 3, n.

Eu Ro PE an JouR nal of MEd I Cal RE SEaRCH november 10, 2011 473 Eur J Med Res (2011) 16: 473-479 I. Holzapfel Publishers 2011 Study of t CEll SubSEtS and Il-7 PRotEIn ExPRESSIon In HIV-1-InfECtEd PatIEntS

Martel-Laferrière V, Brinkley S, Bichoupan K, Posner S, Stivala A, Perumalswami P, Schiano T, Sulkowski M, Dieterich DT, Branch AD

On-treatment and Sustained Virologic Response Rates of Telaprevir-based HCV Treatments Do Not Differ Between HIV/HCV Co-infected and HCV Mono-infected Patients Martel-Laferrière V, Brinkley S, Bichoupan

Tools to Monitor HIV Infection in 2013 and Beyond.

Tools to Monitor HIV Infection in 2013 and Beyond. Federico García, fegarcia@ugr.es Servicio de Microbiología Univ. Hospital San Cecilio Granada, Spain Outline Address clinical questions: Ultra sensitive

Supplementary Fig. 1: Ex vivo tetramer enrichment with anti-c-myc beads

Supplementary Fig. 1: Ex vivo tetramer enrichment with anti-c-myc beads Representative example of comparative ex vivo tetramer enrichment performed in three independent experiments with either conventional

PART II! IMMUNE SENESCENCE!

PART II! IMMUNE SENESCENCE! IMMUNE SENESCENCE! RESEARCH IN HIV Background Senescence: the state of being old or the process or aging Immune senescence: the immune system profile seen in the elderly Does

HIV Management in Resource-Poor Settings

HIV Management in Resource-Poor Settings Research in Progress Eran Bendavid, MD Infectious Diseases Center for Health Policy Outline Context Methods Results Conclusions Discussion Context The number of

Fertility Desires/Management of Serodiscordant HIV + Couples

Fertility Desires/Management of Serodiscordant HIV + Couples William R. Short, MD, MPH Assistant Professor of Medicine Division Of Infectious Diseases Jefferson Medical College of Thomas Jefferson University

PRO 140. First self-administered antibody therapy for HIV in late-stage clinical development. March

PRO 140 First self-administered antibody therapy for HIV in late-stage clinical development March 2018 Forward-Looking Statements This presentation includes forward-looking statements and forward-looking

Evaluation of HIV-1 viral load among mothers under PTMCT program with lymphocytes T CD4 count above 350 cells/µl

Evaluation of HIV-1 viral load among mothers under PTMCT program with lymphocytes T CD4 count above 350 cells/µl W. M. Christelle Nadembèga 1,3, Justin Konaté 1, Désiré Néboua 1, Arsène Zongo 1, Hugues

Hepatitis B. HBV Cure: Insights for the Biotechnology and the Research Analyst Community November 11, Lalo Flores, PhD Global Head HBV R&D

Hepatitis B HBV Cure: Insights for the Biotechnology and the Research Analyst Community November 11, 2016 Lalo Flores, PhD Global Head HBV R&D Infectious Diseases Diseases Infectious 11 Janssen s Vision

Dr Claire Townsend on behalf of EPPICC. Presented at the 2 nd International Workshop on HIV Pediatrics July 2010, Vienna Austria

Response to early antiretroviral treatment in HIV-infected infants: the experience of the European Pregnancy & Paediatric HIV Cohort Collaboration (EPPICC) Dr Claire Townsend on behalf of EPPICC Background

Supplemental Figure 1. Gating strategies for flow cytometry and intracellular cytokinestaining

Supplemental Figure 1. Gating strategies for flow cytometry and intracellular cytokinestaining of PBMCs. Forward scatter area (FSC-A) versus side scatter area (SSC-A) was used to select lymphocytes followed

A Self-Reported Adherence Measure to Screen for Elevated HIV Viral Load in Pregnant and Postpartum Women on Antiretroviral Therapy

A Self-Reported Adherence Measure to Screen for Elevated HIV Viral Load in Pregnant and Postpartum Women on Antiretroviral Therapy Tamsin Phillips, Kirsty Brittain, Claude A. Mellins, Allison Zerbe, Robert

Median (Min Max) CVC 100 mg + EFV placebo + TDF/FTC (N=8) CVC 200 mg + EFV placebo + TDF/FTC (N=10) LLOQ=5.00 ng/ml Time (h)

600 Pharmacokinetics (Pk) of cenicriviroc (cvc) following 100 or 200 mg once-daily Dosing with open-label tenofovir / emtricitabine (tdf/ftc) in hiv-1 infected subjects enrolled in a Phase 2b study David

Supplementary Figure 1. Enhanced detection of CTLA-4 on the surface of HIV-specific

SUPPLEMENTARY FIGURE LEGEND Supplementary Figure 1. Enhanced detection of CTLA-4 on the surface of HIV-specific CD4 + T cells correlates with intracellular CTLA-4 levels. (a) Comparative CTLA-4 levels

Immunophenotyping of rheumatoid arthritis reveals a linkage between. HLA-DRB1 genotype, CXCR4 expression on memory CD4 + T cells, and

Supplementary Material Title: Immunophenotyping of rheumatoid arthritis reveals a linkage between HLA-DRB1 genotype, CXCR4 expression on memory CD4 + T cells, and disease activity. Authors: Yasuo Nagafuchi

Pediatric HIV Cure Research

Pediatric HIV Cure Research HIV Cure Research Training Curriculum Pediatric HIV Cure Research Presented by: Priyanka Uprety,MSPH, PhD Laboratory of Deborah Persaud, MD Johns Hopkins University July 2016

Anumber of clinical trials have demonstrated

IMPROVING THE UTILITY OF PHENOTYPE RESISTANCE ASSAYS: NEW CUT-POINTS AND INTERPRETATION * Richard Haubrich, MD ABSTRACT The interpretation of a phenotype assay is determined by the cut-point, which defines

Influence of Baseline HCV Genotype upon Treatment Outcome of Acute HCV Infection in HIV Co-Infected Individuals

Influence of Baseline HCV Genotype upon Treatment Outcome of Acute HCV Infection in HIV Co-Infected Individuals Christoph Boesecke, Hans-Jürgen Stellbrink, Stefan Mauss, Emma Page, Mark Nelson, Sanjay

14 TH EUROPEAN HIV & HEPATITIS MEETING Abst#_O_06

14 TH EUROPEAN HIV & HEPATITIS MEETING 2016 Abst#_O_06 Patients with pre-existent NRTI- and NNRTI-resistance have a higher risk to lose virological suppression under tenofovir/emtricitabine/rilpivirine

Kaya HDSS, Burkina Faso

Kaya HDSS, Burkina Faso Site Map Brief Introduction Kaya HDSS is located in the North Central region of Burkina Faso (see maps), in the health District of Kaya. It is about 100 km from the capital Ouagadougou.

Journal of Infectious Diseases Advance Access published April 18, Using Ultradeep Pyrosequencing to Study HIV 1 Co receptor Usage in Primary and

Journal of Infectious Diseases Advance Access published April 18, 2013 1 Using Ultradeep Pyrosequencing to Study HIV 1 Co receptor Usage in Primary and Dual Infection Gabriel A. Wagner 1, Mary E. Pacold

Overview of role of immunologic markers in HIV diagnosis

Overview of role of immunologic markers in HIV diagnosis Savita Pahwa, M.D. Departments of Microbiology & Immunology and Pediatrics University of Miami, Miller School of Medicine, Miami, Florida Background:

How to best manage HIV patient?

How to best manage HIV patient? 1 2 Treatment Treatment Failure success HIV therapy = a long life therapy Why do we want to change a suppressive ART? Side effect Comorbidities Reduce drug burden How to

The HIV Cure Agenda. CHIVA Oct Nigel Klein. Institute of Child Health and Great Ormond Street Hospital, London, UK

The HIV Cure Agenda CHIVA Oct 2016 Nigel Klein Institute of Child Health and Great Ormond Street Hospital, London, UK 2 How frequently is HIV cured? The Berlin patient Restriction of HIV entry CD4 is

Advances in HIV science and treatment. Report on the global AIDS epidemic,

HIV biomolecular advances and treatment updates David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia UNAIDS: global l HIV infections

Cascade of medical care to HIV-infected patients in Europe. Cristina Mussini

Cascade of medical care to HIV-infected patients in Europe Cristina Mussini UNAIDS: New HIV treatment target 90% of people tested 90% of people diagnosed with HIV on treatment 90% of people on treatment

Središnja medicinska knjižnica

Središnja medicinska knjižnica Grgić I., Židovec Lepej S., Vince A., Begovac J. (2010) Increased frequency of viral loads above 100,000 HIV-1 RNA copies/ml measured by Roche Cobas TaqMan assay in comparison

Supplement for: CD4 cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, gender and calendar time.

Supplement for: CD4 cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, gender and calendar time. Anne Cori* 1, Michael Pickles* 1, Ard van Sighem 2, Luuk Gras 2,

Anna Maria Geretti on behalf of co-authors Professor of Virology & Infectious Diseases, University of Liverpool Expert Scientist, Roche Pharma

Anna Maria Geretti on behalf of co-authors Professor of Virology & Infectious Diseases, University of Liverpool Expert Scientist, Roche Pharma Research & Early Discovery Funding: Wellcome Trust, National

Therapeutic Immunization with Autologous DC Pulsed with Autologous Inactivated HIV-1 Infected Apoptotic Cells

Therapeutic Immunization with Autologous DC Pulsed with Autologous Inactivated HIV-1 Infected Apoptotic Cells Sharon A. Riddler, MD, MPH University of Pittsburgh May 2008 Slide 1 HIV and DC Vaccines During

Pediatric Patient Information:

New pediatric dosing information for Aptivus, patients 2-18 years of age, approval of New Oral Solution and information on coadministration with midazolam Aptivus (tipranavir) is now available as an oral

Pediatric Antiretroviral Therapy

Update on Pediatric Antiretroviral Therapy Lynne M. Mofenson, M.D. Pediatric, Adolescent and Maternal AIDS Branch National Institute of Child Health and Human Development National Institutes of Health

Clinical Case. Prof.ssa Cristina Mussini

Clinical Case Prof.ssa Cristina Mussini Clinical history Male, born in Ivory Coast in 1968. HIV positive since dal 1998 Risk factor: heterosexual contacts He started antiretroviral therapy in 2001 with

Identification and Characterization of CD4 T cells actively transcribing HIV RNA in Peripheral Blood

Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Identification and Characterization of CD4 T cells actively transcribing

OUTCOMES OF HIV-INFECTED THERAPY INCLUDING

UNIVERSIDADE FEDERAL DA BAHIA FACULDADE DE MEDICINA DA BAHIA PROGRAMA DE PÓS-GRADUAÇÃO EM MEDICINA E SAÚDE OUTCOMES OF HIV-INFECTED PATIENTS RECEIVING RESCUE THERAPY INCLUDING RALTEGRAVIR Patino-Escarcina

A smart and doable investment

90-90-90 A smart and doable investment As of December 2013 Adults and children living with HIV Adults and children newly infected Adult & child deaths due to AIDS 35.0 million [33.2 million 37.2 million]

The effect of systemic exposure to efavirenz, sex and age on the risk of virological nonsuppression in HIV-infected African children.

The effect of systemic exposure to efavirenz, sex and age on the risk of virological nonsuppression in HIV-infected African children. Andrzej Bienczak Paolo Denti, Adrian Cook, Veronica Mulenga, Cissy

VARIATION IN MEASUREMENT OF HIV RNA VIRAL LOAD

VARIATION IN MEASUREMENT OF HIV RNA VIRAL LOAD SOURCES OF VARIATION (RANDOM VS SYSTEMATIC) MAGNITUDE OF EACH SOURCE CONSEQUENCES FOR CONFIDENCE LIMITS AROUND MEASUREMENTS AND CHANGES DATA FROM ROCHE HIV

Mortality in Mycobacterium tuberculosis patients coinfected with human immunodeficiency virus before and in the era of antiretroviral therapy

Mortality in Mycobacterium tuberculosis patients coinfected with human immunodeficiency virus before and in the era of antiretroviral therapy Belete Tegbaru 1,2, Tsehaynesh Messele 1, Mesfin Kebede 3,

Prevalence, type and factors associated with HPV infection at multiple sites in young HIV- positive MSM

Prevalence, type and factors associated with HPV infection at multiple sites in young HIV- positive MSM On behalf of the HPV MAPS Research Group C Sadlier 1,2, S O Dea 1, S Delamere 1, P Smyth 3, N Myers

Supplementary Online Content

Supplementary Online Content Peters PJ, Westheimer E, Cohen S, et al. Screening yield of HIV antigen/antibody combination and pooled HIV RNA testing for acute HIV infection in a high-prevalence population.

MANITOBA HIV REPORT 2015

MANITOBA HIV REPORT 2015 The Manitoba HIV Program provides information, specialized care, treatment, and support to approximately 1,250 people living with HIV across the province. The Program has two Winnipeg-based

NOTICE TO PHYSICIANS. Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health

NOTICE TO PHYSICIANS DATE: March 10, 2003 TO: FROM: SUBJECT: HIV/AIDS Health Care Providers Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health

Dolutegravir Attributes

Dolutegravir (; S/GSK1349572) in Combination Therapy Exhibits Rapid and Sustained Antiviral Response in Antiretroviral Naïve Adults: 96 Week Results from SPRING 1 (ING112276) Hans Juergen Stellbrink, 1

Cryptococcosis of the Central Nervous System: Classical and Immune-Reconstitution Disease

Cryptococcosis of the Central Nervous System: Classical and Immune-Reconstitution Disease Assist Prof. Somnuek Sungkanuparph Division of Infectious Diseases Faculty of Medicine Ramathibodi Hospital Mahidol

Glecaprevir-Pibrentasvir in Cirrhotic Genotype 1, 2, 4, 5, and 6 EXPEDITION-1

Phase 3 Treatment-Naïve and Treatment-Experienced Glecaprevir-Pibrentasvir in Cirrhotic Genotype 1, 2, 4, 5, and 6 EXPEDITION-1 EXPEDITION-1: Study Features EXPEDITION-1 Trial Design: Open-label, single-arm,

Update on HIV-1 Drug Resistance and Tropism Testing

Update on HIV-1 Drug Resistance and Tropism Testing Daniel R. Kuritzkes, MD Section of Retroviral Therapeutics Brigham and Women s Hospital Harvard Medical School ACTHIV 2011: A State-of-the-Science Conference

Clinical skills building - HIV drug resistance

Clinical skills building - HIV drug resistance Richard Lessells Clinical case 44-year old HIV-positive male HIV diagnosis 2010 Pre-treatment CD4+ count not known Initiated first-line ART (TDF/FTC/EFV)

Dynamics of Compartmentalized HIV-1 Populations in the Central Nervous System Patrick R. Harrington

Dynamics of Compartmentalized HIV-1 Populations in the Central Nervous System Patrick R. Harrington Postdoctoral Fellow Laboratory of Ronald Swanstrom Lineberger Comprehensive Cancer Center University

Supplemental Figure 1. IL-3 blockade with Fab CSL362 depletes plasmacytoid dendritic cells (pdcs), but not basophils, at higher doses.

Supplemental Figure 1. IL-3 blockade with Fab CSL362 depletes plasmacytoid dendritic cells (pdcs), but not basophils, at higher doses. Percentage of viable (A) pdcs (Sytox Blue-, Lin1-, HLADR+, BDCA2++)

Individual Study Table Referring to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI424136

Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Reyataz Name of Active Ingredient: Individual Study Table Referring to the Dossier (For National Authority Use Only) SYNOPSIS for

Highly active antiretroviral (ARV) therapy (HAART) has dramatically

ORIGINAL STUDIES Pattern and Predictors of Immunologic Recovery in Human Immunodeficiency Virus-Infected Children Receiving Non-Nucleoside Reverse Transcriptase Inhibitor-Based Highly Active Antiretroviral

INTERNATIONAL WORKSHOP ON HIV PEDIATRICS - JULY

PHARMACOKINETIC AND 4-WEEK SAFETY/EFFICACY OF DOLUTEGRAVIR (S/GSK1349572) DISPERSIBLE TABLETS IN HIV-INFECTED CHILDREN AGED 4 WEEKS TO

ORIGINAL RESEARCH. Introduction

DOI: 10.1111/j.1468-1293.2008.00664.x HIV Medicine (2009), 10, 152 156 ORIGINAL RESEARCH r 2009 British HIV Association Impact of a modified directly administered antiretroviral treatment intervention

Management of patients with antiretroviral treatment failure: guidelines comparison

The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral

Supplementary Materials for

www.sciencetranslationalmedicine.org/cgi/content/full/8/352/352ra110/dc1 Supplementary Materials for Spatially selective depletion of tumor-associated regulatory T cells with near-infrared photoimmunotherapy